GMC Jammu Offers Genetic Cancer Testing With Next Gen Tech.
SRINAGAR: For the very first time, the Government Medical College Jammu has initiated genetic cancer testing using Next Generation Technology.
An official informed the news agency that the Department of Microbiology at GMC Jammu has successfully started genetic testing for BRCA1 and BRCA2 mutations using cutting-edge Next Generation Sequencing (NGS) technology.
He said the initiative aims to enhance capacity in genetic sequencing and provide the most advanced technology in diagnostics and research. NGS is being utilized in oncogenetic testing for BRCA1 and BRCA2 genes, targeting harmful mutations that predispose individuals or their relatives to cancer.
“Mutations in the BRCA1 or BRCA2 genes can significantly increase the risk of developing breast cancer, making up to 65-85% for BRCA1 mutations and 40-85% for BRCA2 mutations by the age of 70,” he said, adding, “Positive BRCA1 or BRCA2 results enable individuals to make informed decisions about available options to potentially reduce their risk of developing breast cancer.”
The department also plans to gradually incorporate Human Papillomavirus NGS testing in the second phase.
Dr Sandeep Dogra, Head of the Department of Microbiology at GMC Jammu, said this technology represents the forefront of diagnostics and resources. By identifying genetic mutations before symptoms appear, this cutting-edge technology allows for tailored therapies based on individual requirements, he said.
Dr Dogra explained, “The testing usually takes 7-10 days, with multiple people being tested simultaneously. Currently, these facilities are provided free of cost at the hospital and involve specialised machinery and expertise. Such tests are conducted based on recommendations from oncologists.”
He said such tests are being on the recommendations of oncologists. Once such probability is found in any person, then a clinical oncologist can advise him and offer different things that he can adapt, he said, adding that in the next five to ten years, diagnosis will be based on genetics and it helps in catching disease very early.
Officials said that NGS technology has revolutionised cancer genetic testing by offering a deeper understanding of tumour genetics and guiding personalised treatment strategies. It enables simultaneous analysis of multiple genes, enhancing diagnostic accuracy, identifying therapeutic targets, predicting treatment response, and monitoring tumour evolution over time, they said.
“NGS facilitates the detection of rare genetic mutations and allows monitoring of tumour evolution over time. It also aids in the early detection of treatment resistance and guides adjustments in therapy,” the officials said—(KNO)